VCANBIO(600645)2025-04-24 14:45Financial Performance - Revenue for the first quarter was CNY 350,790,044.48, a decrease of 11.86% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 30.18% to CNY 28,030,417.80[4] - Basic and diluted earnings per share both decreased by 33.33% to CNY 0.06[4] - Total operating revenue for Q1 2025 was CNY 350,790,044.48, a decrease of 11.85% compared to CNY 397,981,195.71 in Q1 2024[17] - Net profit for Q1 2025 was CNY 25,554,539.25, representing a decline of 38.39% from CNY 41,500,411.38 in Q1 2024[18] - The total profit for Q1 2025 was CNY 36,274,765.27, a decrease of 36.14% from CNY 56,753,233.47 in Q1 2024[17] - The total comprehensive income for Q1 2025 was CNY 23,668,355.70, down from CNY 34,730,937.04 in Q1 2024[18] Cash Flow and Operating Activities - Net cash flow from operating activities increased by 116.56% to CNY 46,398,618.68, primarily due to reduced cash payments for goods and services[6] - The net cash flow from operating activities for Q1 2025 was CNY 46,398,618.68, an increase of 117.79% compared to CNY 21,424,807.24 in Q1 2024[20] - The company reported a net cash increase of CNY 26,421,366.46 in Q1 2025, compared to a decrease of CNY 61,147,234.13 in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,248,825,312.86, showing no significant change from the previous year[5] - The company's total liabilities decreased from RMB 1,589,880,909.12 to RMB 1,566,091,503.50, indicating a reduction of approximately 1.96%[14] - Cash and cash equivalents rose to RMB 1,551,411,991.22 from RMB 1,524,990,910.90, marking an increase of approximately 1.73%[12] - Accounts receivable slightly decreased from RMB 609,136,583.85 to RMB 605,065,698.13, a decline of about 0.34%[12] - Inventory increased from RMB 232,194,124.88 to RMB 236,839,792.84, representing a growth of approximately 2.76%[12] Shareholder Information - The company reported a total of 34,948 common shareholders at the end of the reporting period[8] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., holds 12.14% of the shares[8] - Shareholders' equity attributable to shareholders increased by 0.73% to CNY 3,621,231,799.18[5] - The weighted average return on equity decreased by 0.31 percentage points to 0.78%[5] Research and Development - Research and development expenses for Q1 2025 were CNY 38,582,620.51, a decrease of 12.00% from CNY 43,793,779.30 in Q1 2024[17] Foreign Exchange and Other Income - The company experienced a foreign exchange loss of CNY 1,339,995.40 in Q1 2025, compared to a gain of CNY 1,793,398.34 in Q1 2024[21] - The company received government subsidies amounting to CNY 232,527.68 during the reporting period[6] Pledges and Financing - The company has pledged 32,723,260 shares to Shenzhen Jiadao Success Investment Enterprise, with a pledge expiration date of April 20, 2027[10] - The company has not reported any significant changes in the participation of major shareholders in margin financing and securities lending activities[10]